Masimo (NASDAQ:MASI - Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Masimo to post earnings of $1.42 per share and revenue of $593.35 million for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.
Masimo Trading Down 4.1 %
Shares of NASDAQ:MASI traded down $7.25 during midday trading on Friday, hitting $169.96. The company had a trading volume of 603,597 shares, compared to its average volume of 475,070. Masimo has a 12 month low of $101.61 and a 12 month high of $184.51. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.10 billion, a price-to-earnings ratio of 117.21 and a beta of 1.02. The firm has a fifty day simple moving average of $172.90 and a 200 day simple moving average of $151.29.
Wall Street Analyst Weigh In
Several research firms have weighed in on MASI. Piper Sandler lifted their target price on Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Stifel Nicolaus reiterated a "buy" rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Wells Fargo & Company lifted their target price on Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Raymond James lifted their target price on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $191.40.
Read Our Latest Research Report on MASI
Masimo Company Profile
(
Get Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Further Reading
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
